Drug intelligence / Profile preview

METOral Peptide

Development stage: Preclinical
Lead developer: Nanomerics
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Oral

Overview

METOral Peptide is a preclinical-stage drug candidate being developed by Nanomerics for the treatment of diabetes. The candidate utilizes the company's proprietary METOral (Molecular Envelope Technology) platform, which is a nanoparticle-based delivery system designed to enable the oral administration of peptides. This technology aims to protect the peptide cargo from the harsh environment of the gastrointestinal tract and facilitate its transport across the intestinal epithelium into the bloodstream. While the specific identity of the peptide and its biological target have not been disclosed, the program represents an effort to transition injectable peptide treatments for diabetes into more patient-friendly oral formulations.

Other names: METOral Peptide platform

Beyond the preview

Go deeper on METOral Peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METOral Peptide.

Explore the full profile